Sanguinarine suppresses prostate tumor growth and inhibits survivin expression.

Prostate cancer is a frequently occurring disease and is the second leading cause of cancer-related deaths of men in the United States. Current treatments have proved inadequate in curing or controlling prostate cancer, and a search for agents for the management of this disease is urgently needed. Survivin plays an important role in both progression of castration-resistant prostate cancer and resistance to chemotherapy. Altered expression of survivin in prostate cancer cells is associated with cancer progression, drug/radiation resistance, poor prognosis, and short patient survival. In the present study, the authors performed a cell-based rapid screen of the Prestwick Chemical Library consisting of 1120 Food and Drug Administration-approved compounds with known safety and bioavailability in humans to identify potential inhibitors of survivin and anticancer agents for prostate cancer. Sanguinarine, a benzophenanthridine alkaloid derived primarily from the bloodroot plant, was identified as a novel inhibitor of survivin that selectively kills prostate cancer cells over "normal" prostate epithelial cells. The authors found that sanguinarine inhibits survivin protein expression through protein degradation via the ubiquitin-proteasome system. Sanguinarine induces apoptosis and inhibits growth of human prostate cancer cells and in vivo tumor formation. Administration of sanguinarine, beginning 3 days after ectopic implantation of DU145 human prostate cancer cells, reduces both tumor weight and volume. In addition, sanguinarine sensitized paclitaxel-mediated growth inhibition and apoptosis, offering a potential therapeutic strategy for overcoming taxol resistance. These results suggest that sanguinarine may be developed as an agent either alone or in combination with taxol for treatment of prostate cancer overexpressing survivin.

[1]  Zhiwei Wang,et al.  3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation. , 2009, Cancer research.

[2]  Y. Sekine,et al.  Gene expression of survivin and its spliced isoforms associated with proliferation and aggressive phenotypes of prostate cancer. , 2008, Urology.

[3]  B. Klejdus,et al.  The toxicity and pharmacokinetics of dihydrosanguinarine in rat: a pilot study. , 2008, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[4]  Tae-Jin Lee,et al.  Sanguinarine‐induced apoptosis: Generation of ROS, down‐regulation of Bcl‐2, c‐FLIP, and synergy with TRAIL , 2008, Journal of cellular biochemistry.

[5]  S. Hatakeyama,et al.  YM155, a novel small-molecule survivin suppressant, induces regression of established human hormone-refractory prostate tumor xenografts. , 2007, Cancer research.

[6]  Fengzhi Li,et al.  Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter , 2007, Molecular Cancer Therapeutics.

[7]  L. Platanias,et al.  Sanguinarine-dependent induction of apoptosis in primary effusion lymphoma cells. , 2007, Cancer research.

[8]  B. Spaulding,et al.  Characterization of the 12C4 survivin monoclonal antibody and insight into the expression of survivin in human adult tissues , 2006, Histopathology.

[9]  R. Larsson,et al.  Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. , 2006, Anticancer research.

[10]  Fengzhi Li,et al.  Survivin study: An update of “What is the next wave?” , 2006, Journal of cellular physiology.

[11]  Fengzhi Li,et al.  Role of the Survivin gene in pathophysiology. , 2006, The American journal of pathology.

[12]  D. Panda,et al.  The benzophenanthridine alkaloid sanguinarine perturbs microtubule assembly dynamics through tubulin binding , 2006, The FEBS journal.

[13]  A. Sorokin,et al.  Cyclooxygenase 2 rescues LNCaP prostate cancer cells from sanguinarine-induced apoptosis by a mechanism involving inhibition of nitric oxide synthase activity. , 2006, Cancer research.

[14]  G. Colombo,et al.  Rational design of shepherdin, a novel anticancer agent. , 2005, Cancer cell.

[15]  A. Chakravarti,et al.  Survivin mediates resistance to antiandrogen therapy in prostate cancer , 2005, Oncogene.

[16]  A. Mukherjee,et al.  Sanguinarine: an evaluation of in vivo cytogenetic activity. , 2004, Mutation research.

[17]  Hasan Mukhtar,et al.  Sanguinarine causes cell cycle blockade and apoptosis of human prostate carcinoma cells via modulation of cyclin kinase inhibitor-cyclin-cyclin-dependent kinase machinery. , 2004, Molecular cancer therapeutics.

[18]  H. Shiina,et al.  Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. , 2004, The Journal of urology.

[19]  G. Koh,et al.  Suppression of angiogenesis by the plant alkaloid, sanguinarine. , 2004, Biochemical and biophysical research communications.

[20]  Fengzhi Li,et al.  Induction of Survivin Expression by Taxol (Paclitaxel) Is an Early Event, Which Is Independent of Taxol-mediated G2/M Arrest* , 2004, Journal of Biological Chemistry.

[21]  Fengzhi Li,et al.  Silencing of antiapoptotic survivin gene by multiple approaches of RNA interference technology. , 2004, BioTechniques.

[22]  C. Roehrborn,et al.  Survivin expression is associated with features of biologically aggressive prostate carcinoma , 2004, Cancer.

[23]  C. Duckett,et al.  Acute Ablation of Survivin Uncovers p53-dependent Mitotic Checkpoint Functions and Control of Mitochondrial Apoptosis* , 2004, Journal of Biological Chemistry.

[24]  A. Vitiello,et al.  Elevated expression of inhibitor of apoptosis proteins in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  Fengzhi Li.  Survivin study: What is the next wave? , 2003, Journal of cellular physiology.

[26]  V. Adhami,et al.  Activation of prodeath Bcl-2 family proteins and mitochondrial apoptosis pathway by sanguinarine in immortalized human HaCaT keratinocytes. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[27]  A. Buck,et al.  Triplex-forming oligodeoxynucleotides targeting survivin inhibit proliferation and induce apoptosis of human lung carcinoma cells , 2003, Cancer Gene Therapy.

[28]  J. Madelmont,et al.  Sanguinarine-induced apoptosis is associated with an early and severe cellular glutathione depletion , 2003, Cancer Chemotherapy and Pharmacology.

[29]  Tae Ho Lee,et al.  Ribozyme-mediated cleavage of the human survivin mRNA and inhibition of antiapoptotic function of survivin in MCF-7 cells , 2003, Cancer Gene Therapy.

[30]  Y. Pommier,et al.  Suppression of survivin phosphorylation on Thr34 by flavopiridol enhances tumor cell apoptosis. , 2003, Cancer research.

[31]  K. Uematsu,et al.  Induction of apoptosis in mesothelioma cells by antisurvivin oligonucleotides. , 2002, Molecular cancer therapeutics.

[32]  M. Daidone,et al.  Ribozyme-mediated attenuation of survivin expression sensitizes human melanoma cells to cisplatin-induced apoptosis. , 2002, The Journal of clinical investigation.

[33]  J. Li,et al.  Cancer gene therapy using a survivin mutant adenovirus. , 2001, The Journal of clinical investigation.

[34]  J. Downward,et al.  The ubiquitin-proteasome pathway regulates survivin degradation in a cell cycle-dependent manner. , 2000, Journal of cell science.

[35]  Hui Zhang,et al.  Regulation of apoptosis at cell division by p34cdc2 phosphorylation of survivin. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. Fabbro,et al.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. , 2000, Cancer research.

[37]  John Calvin Reed,et al.  Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth. , 2000, Neoplasia.

[38]  J. McNiff,et al.  Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma. , 1999, The Journal of investigative dermatology.

[39]  Fengzhi Li,et al.  Pleiotropic cell-division defects and apoptosis induced by interference with survivin function , 1999, Nature Cell Biology.

[40]  D. Altieri,et al.  Transcriptional analysis of human survivin gene expression. , 1999, The Biochemical journal.

[41]  G. Landes,et al.  Analysis of human transcriptomes , 1999, Nature Genetics.

[42]  J. McNiff,et al.  Expression of the apoptosis inhibitor, survivin, in nonmelanoma skin cancer and gene targeting in a keratinocyte cell line. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[43]  D. Altieri,et al.  The cancer antiapoptosis mouse survivin gene: characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression. , 1999, Cancer research.

[44]  Fengzhi Li,et al.  Control of apoptosis and mitotic spindle checkpoint by survivin , 1998, Nature.

[45]  A. Goldberg,et al.  Proteasome inhibitors: valuable new tools for cell biologists. , 1998, Trends in cell biology.

[46]  D. Altieri,et al.  A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma , 1997, Nature Medicine.

[47]  L. Mitscher,et al.  Antimicrobial agents from higher plants. An investigation of Hunnemannia fumariaefolia pseudoalcoholates of sanguinarine and chelerythrine. , 1978, Lloydia.

[48]  L. Mitscher.  Antimicrobial Agents from Higher Plants , 1975 .